ReviewNPJ Regenerative medicine2020
Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.
Review in NPJ Regenerative medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- A Barrier to Defend - Models of Pulmonary Barrier to Study Acute Inflammatory Diseases.Frontiers in immunology · 2022Pooled it
- Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.Stem cells translational medicine · 2021Trial
- Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.Clinical and translational medicine · 2021Trial
- Conditioned media from adipose-derived mesenchymal stem cells improves movento induced lung damage in male rats.BMC pulmonary medicine · 2025Article
- A Comparative Analysis of MicroRNA Expression in Mild, Moderate, and Severe COVID-19: Insights from Urine, Serum, and Nasopharyngeal Samples.Biomolecules · 2023Article
- Procoagulant Activity of Umbilical Cord-Derived Mesenchymal Stromal Cells' Extracellular Vesicles (MSC-EVs).International journal of molecular sciences · 2023Article
- The efficacy of bone marrow mesenchymal stem cells on rat intestinal immune-function injured by ischemia/reperfusion.Heliyon · 2023Article
- A risk assessment study of SARS-CoV-2 propagation in the manufacturing of cellular products.Regenerative medicine · 2023Review
- Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases.Human cell · 2022Review
- Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method.Expert opinion on biological therapy · 2022Article
- Safety study of allogeneic mesenchymal stem cell therapy in animal model.Regenerative therapy · 2022Article
- Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.Cellular and molecular life sciences : CMLS · 2022Review
- miRNAs: The Key Regulator of COVID-19 Disease.International journal of cell biology · 2022Review
- Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System.Stem cell reviews and reports · 2021Review
- The Immunopathobiology of SARS-CoV-2 Infection.FEMS microbiology reviews · 2021Article
- Review
- Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach.Stem cells translational medicine · 2021Review
- Mesenchymal stem cells and COVID-19: What they do and what they can do.World journal of stem cells · 2021Review
- Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs), multipotent stromal cells that mediate immunomodulation and regeneration, could be of potential benefit to a subset of COVID-19 subjects with acute respiratory failure. In this review, we discuss key features of the current COVID-19 outbreak, and the rationale for MSC-based therapy in this setting, as well as the limitations associated with this therapeutic approach.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.